Natural Killer Cells Therapies Competitive Landscape, also known as NK Cells are a type of lymphocytes and are key components of the innate immune system. They are highly specific predators that play a major role in the host rejection of both tumors and viral infected cells. Natural Killer Cell have cytotoxic small granules which contain special proteins such as perforins and proteases are known as granzymes in their cytoplasm.
Perforins form pores in the cell membrane of the target cell through which the granzymes and associated molecules induce apoptosis. Natural Killer Cell are derived from the common lymphoid progenitor cells (lymphoblasts), which also generate B and T lymphocytes. They differentiate and mature in the bone marrow, lymph nodes, spleen, tonsils, and thymus, where they then enter into the bloodstream.
“Natural Killer Cell Therapies - Competitive Landscape, Technology and Natural Killer Cell Therapies Pipeline Analysis, 2021” report provides comprehensive insights on the therapeutic development for this mechanism of action. The objective of the report is to establish an understanding of the therapeutic competitive landscape for Natural Killer Cell Therapies, including the pipeline products in this space.
It further offers comparative pipeline analysis with their drug profiles at various stages of development covering Phase III, Phase II, Phase I, Preclinical and Discovery. Information on company collaborations, agreements, acquisitions, Natural Killer Cell Therapies licensing, deals, and other development activities is also involved in this report Therapeutics assessment of active pipeline drugs by stage, therapy type, route of administration, and molecule type is also covered in this report.
It features the inactive pipeline products and highlights currently undergoing institutional research in this area. The report provides the information related to several technologies in development of the molecules based on the Natural Killer Cell Therapies mechanism. The report provides the understanding of the unmet needs of the Natural Killer Cell Therapies market.
Future competitive landscape of Natural Killer Cell Therapies is estimated to be very strong. Key emerging drugs including Nektar Therapeutics’ NKTR-214, Five Prime Therapeutics’ Bemarituzumab, Affimed Therapeutics’ AFM-13, Green Cross Corporation’s MG 4101 and others are going to be Blockbuster in the upcoming years.
Know More About- Natural Killer Cell Therapies Key Players